On the morning of June 12, 2026, the 2nd Global Cardiovascular Conference was held at the Beijing Zhongguancun Exhibition Center Conference Hall.

As an important component of the 2026 Global MedTech Conference Series, this conference was co-hosted by MedTech (Siyu MedTech) and CardioFuture, and co-organized by the Zhongguancun United Innovative Biomedical Industry Alliance, Beijing Zhongguancun Science City Innovation and Development Co., Ltd., Beijing Zhongguancun Science City Innovation and Technology Service Co., Ltd., China Beijing (Haidian) Overseas Chinese Scholars Pioneer Park, and TusStar Medical-Engineering Interdisciplinary Innovation Center.

The conference focused on hot directions including cardiovascular device innovation, medical technology transfer, structural heart disease, biomedical materials, mechanical design, and intravascular imaging, attracting over 600 guests from medical institutions, research institutes, investment organizations, and industry to exchange views and jointly explore innovation and growth opportunities in China's cardiovascular industry.

Opening Address

Xiao Jing, Director of Industry Division III, Zhongguancun Science City Management Committee, delivered the opening address.

She introduced the development of the pharmaceutical and health industry in Haidian District and stated that Haidian is continuously improving its innovation ecosystem, promoting the aggregation of innovation resources, supporting collaborative innovation among medical device enterprises, clinical institutions, and universities/research institutes, and accelerating the transfer and implementation of scientific and technological achievements, providing support for high-quality development of the pharmaceutical and health industry.

Spotlight on Innovation Pathways, Discussing the Future of the Industry

Zhao Qing, Editor-in-Chief of MedTech (Siyu MedTech) and CardioFuture, and Secretary-General of the Zhongguancun United Innovative Biomedical Industry Alliance, delivered a keynote presentation titled "The Next Chapter of Cardiovascular Innovation: From Device Innovation to Treatment Pathway Reconstruction."

Combining research findings from the China Innovative Medical Devices White Paper 2026, she systematically reviewed the current development status of domestic cardiovascular innovative devices and analyzed development trends in segments such as structural heart disease, electrophysiology, artificial hearts, and intravascular imaging. She stated that Chinese enterprises have completed domestic substitution for a large number of mature products, and that in the next stage, greater attention should be paid to exploring new treatment pathways and innovation directions centered on clinical outcomes, treatment efficiency, safety, payment accessibility, and global market demand.

Wu Guanghui, Associate Researcher at the Science and Technology Division of Beijing Anzhen Hospital, Capital Medical University / Beijing Institute of Heart, Lung and Blood Vessel Diseases, delivered a keynote presentation titled "Innovation System Construction and Technology Transfer Practice at Anzhen Hospital."

Combining Anzhen Hospital's development in recent years, he shared the hospital's exploration in building an innovation system around technology innovation and technology transfer. Through measures such as improving institutional construction, increasing research investment, optimizing evaluation mechanisms, and building concept verification centers and innovation platforms, the hospital is gradually forming an innovation ecosystem covering basic research, clinical research, achievement incubation, and industrial transformation, while continuously driving more innovative achievements from the laboratory toward clinical application and industrial implementation.

Li Yingjun, Chairman of Beijing Tonghe Litai Biotechnology Co., Ltd., delivered a keynote presentation titled "Cardiovascular Medical Devices and Biomedical Materials."

Combining the burden of cardiovascular diseases, industry development trends, and material technology evolution, he systematically reviewed the industry's future development directions and shared development opportunities in segments such as structural heart disease, electrophysiology, and intravascular imaging. In his view, every generation of important breakthroughs in cardiovascular devices has been driven by the combined forces of material innovation and clinical needs, and the industry will continue to evolve in multiple directions over the next decade, including biodegradable technology, artificial heart valves, electrophysiology, regenerative medicine, and intelligent implantable devices.

Cai Longsheng, R&D Head of the Structural Heart Disease Division at Genesis MedTech Group, delivered a keynote presentation titled "From No Global Solution to Global Leadership: How a China-Original Valve Conquered the World-Class Challenge of Aortic Regurgitation."

Focusing on aortic regurgitation, a clinical challenge that has long lacked mature interventional treatment solutions, he introduced the R&D journey and innovation concept of J-Valve. Addressing challenges such as the lack of calcified anchor points in regurgitation patients and the difficulty of stable fixation with traditional TAVI products, the team innovatively proposed a "bidirectional anchoring" design, achieving stable valve implantation through movable positioning keys, providing a new treatment option for aortic regurgitation patients. Currently, J-Valve has completed over 10,000 clinical applications and has established two technical routes — transapical and transfemoral — providing a new practical example for China-original high-end medical devices moving toward international markets.

Li Fang, R&D Head of Enlight Medical Technologies (Shanghai) Co., Ltd., delivered a keynote presentation titled "From Clinical Pain Points to Device Innovation: The Pragmatic Innovation of a Mitral Valve Clip."

Focusing on real clinical needs in mitral regurgitation interventional therapy, he shared the product development concept of Enlight Medical's mitral valve clip. Addressing clinical pain points such as unilateral leaflet detachment, long-term fatigue failure, slow endothelialization, and long learning curves, the team continuously optimized product performance from multiple dimensions including material selection, structural design, human-machine interaction, and catheter control, achieving clip weight reduction, stress reduction, and improved operational convenience. He stated that in the future, mitral valve repair technology will continue to evolve toward material innovation, precision control, and intelligent assistance, making complex surgeries more standardized, precise, and accessible.

Liu Yingquan, Head of Medical Technology Transfer Business at the China Technology Exchange, delivered a keynote presentation titled "Compliance Pathways for Medical Technology Transfer."

Combining the development trajectory of national technology transfer policies in recent years, he systematically reviewed the entire process of medical technology achievements from innovation discovery, intellectual property layout, achievement maturation, to industrial implementation, and focused on introducing major transfer models such as achievement transfer, licensing, and valuation investment, as well as the role of technology trading platforms in achievement pricing, open trading, and risk prevention and control. He stated that establishing sound institutional processes, intellectual property management mechanisms, and professional service systems is an important foundation for driving high-quality implementation of innovative achievements.

Sun Anqiang, Professor at Beihang University, delivered a keynote presentation titled "Mechanical Design in Cardiovascular Medical Devices."

From the perspective of hemodynamics, he introduced the important role of mechanics research in cardiovascular disease diagnosis, risk assessment, and device R&D, and combined cases such as covered stents, flow-diverting stents, artificial hearts, and artificial heart valves to share application practices of fluid dynamics simulation, in vitro testing platforms, and digital technologies in product design optimization. He believes that with the development of new technologies such as AI and digital twins, mechanical analysis will play an increasingly important role in device design, performance evaluation, and product review.

Wang Tao, Marketing Director of HORIMED, delivered a keynote presentation titled "Breakthrough and Evolution of Domestic Intravascular Imaging."

He reviewed the nearly 30-year development journey of China's intravascular imaging market, from early dominance by imported brands, to domestic enterprises gradually achieving technological breakthroughs and market substitution, and then to rapid adoption driven by centralized procurement in recent years, systematically reviewing the development paths of IVUS and OCT domestically. He stated that as clinical evidence continues to improve, penetration rates continue to increase, and domestic product performance advances, intravascular imaging is gradually moving from an "optional tool" to an important component of complex coronary intervention. Regarding future development directions, he also shared the latest explorations in fields such as multimodal fusion imaging, AI-assisted diagnosis, and local evidence-based research, believing that Chinese enterprises have the opportunity to participate in the establishment of global industry standards and drive domestic intravascular imaging from following to leading.

The Zhongguancun United Innovative Biomedical Industry Alliance (ZLSHIA) is a formally registered non-profit corporate entity under the Beijing Civil Affairs Bureau, aimed at responding to national strategic planning for the biomedical industry, building government-enterprise exchange platforms, voicing for the biomedical industry alliance, promoting industry-academia-research collaborative innovation, and boosting the development of the biomedical industry.

The alliance's predecessor was the "Zhongguancun Biomedical Industry Alliance." In 2015, it was registered as the "Zhongguancun United Innovative Biomedical Industry Alliance" in accordance with Civil Affairs Bureau requirements. "Lianxin" (Lianxin) means united innovation.

The alliance recruits enterprise and research institution members from across the country in the biomedical field.

The alliance provides various resource docking services for member units. It has cumulatively participated in promoting 15 industrial policy innovations; led or participated in the formulation of over 20 biomedical industry policies or industrial plans for governments at all levels nationwide; led or participated in over 30 biomedical industrial park construction planning and consulting projects nationwide; led or recommended member units to participate in over 50 major science and technology or platform projects; and hosted or co-hosted over 500 exhibitions, forums, and salon events.

Organizations interested in joining the alliance may directly contact the Secretariat: Zhao Qing, WeChat ID: qingzhao2017

June 12, 2026